Lyka Labs Share Price | Lyka Labs Stock Screener
LYKALABS
Pharmaceuticals
Share Price NSE
₹73.95
▲
0.91 (1.25%)
Share Price BSE
₹72.00
▲
0.00 (0.00%)
As of June 30, 2026, the Lyka Labs share price (NSE: LYKALABS) is ₹73.95 on NSE and ₹72.00 on BSE, up 1.25% from the previous close, with shares trading between ₹71.00 and ₹74.80, and a 52-week range of ₹44.95–₹116.18.
Analyse LYKALABS share price charts and track historical price performance.
Use the Lyka Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Lyka Labs Market Cap
₹254.90 Cr.
LYKALABS P/E Ratio (TTM)
-24.91
Lyka Labs P/B Ratio
2.80
EPS (TTM)
₹-2.81
Dividend Yield
-
Debt to Equity
0.55
LYKALABS 52 Week High
₹116.18
Lyka Labs 52 Week Low
₹44.95
Operating Margin
-23.00%
Profit Margin
-27.59%
LYKALABS Revenue (TTM)
₹29.00
EBITDA
₹-6.00
Net Income
₹-8.00
Total Assets
₹175.00
Total Equity
₹92.00
Lyka Labs Share Price Chart
Screen Lyka Labs share price with an interactive chart. Analyse LYKALABS price trends and volatility across different timeframes.
Lyka Labs Company Profile - Fundamental Screener
Screen Lyka Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LYKALABS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE933A01014
Lyka Labs Balance Sheet Screener
Screen LYKALABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 175 | 176 | 157 | 152 | 186 | 190 | 200 | 216 | 229 | 252 |
| Current Assets | 63 | 67 | 51 | 44 | 52 | 29 | 36 | 35 | 49 | 63 |
| Fixed Assets | 89 | 85 | 58 | 68 | 94 | 98 | 105 | 108 | 116 | 133 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 30 | 26 | 51 | 73 | 73 | 165 | 149 | 85 | 9 | 42 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 92 | 104 | 68 | 46 | 14 | -25 | -15 | 46 | 53 | 45 |
| Share Capital | 36 | 36 | 33 | 31 | 29 | 29 | 29 | 28 | 28 | 22 |
| Reserves & Surplus | 57 | 68 | 26 | -3 | -15 | -55 | -43 | 14 | 21 | 16 |
Lyka Labs Income Statement Screener - Profit & Revenue Analysis
Screen Lyka Labs income statement and profit fundamentals.
Analyze LYKALABS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Lyka Labs share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29 | 34 | 34 | 38 | 32 | 28 | 31 | 41 | 35 | 23 | 23 | 28 | 33 | 36 | 28 |
| Expenses | 35 | 29 | 29 | 39 | 29 | 26 | 26 | 36 | 29 | 19 | 20 | 24 | 26 | 25 | 21 |
| EBITDA | -6 | 5 | 4 | -2 | 3 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 7 | 10 | 7 |
| Operating Profit % | -23.00% | 12.00% | 11.00% | -7.00% | 5.00% | 7.00% | 12.00% | 12.00% | 15.00% | 13.00% | 12.00% | 13.00% | 21.00% | 28.00% | 23.00% |
| Depreciation | 2 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 4 | 4 | 3 | 10 | 4 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 3 |
| Profit Before Tax | -9 | 3 | 1 | -4 | 0 | -2 | 2 | 3 | 4 | -3 | -2 | -1 | 3 | -2 | 1 |
| Tax | -1 | 1 | 0 | -1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 13 | 0 |
| Net Profit | -8 | 2 | 1 | -3 | 0 | -2 | 1 | 2 | 3 | -3 | -2 | -1 | 2 | -15 | 1 |
| EPS | -2.13 | 0.49 | 0.25 | -0.94 | 0.00 | -3.83 | 0.40 | 0.58 | 0.75 | -1.05 | -0.57 | -0.15 | 0.53 | -5.26 | 0.20 |
Lyka Labs Cash Flow Screener - Liquidity Fundamentals
Screen LYKALABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 2 | 2 | 9 | 79 | 9 | 5 | 27 | 11 | 31 | 12 |
| Investing Activities | -12 | -10 | 7 | -6 | 0 | 0 | -4 | -3 | -13 | 17 |
| Financing Activities | 5 | 2 | -22 | -63 | -12 | 3 | -23 | -10 | -19 | -30 |
| Net Cash Flow | -5 | -6 | -5 | 10 | -3 | 9 | -1 | -3 | 0 | -1 |
Lyka Labs Shareholding Pattern Screener
See Lyka Labs shareholding pattern with promoter, FII, and DII holdings.
Check Lyka Labs promoter holding and ownership changes for LYKALABS on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Apr | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 58.16% | 58.16% | 58.16% | 58.16% | 58.16% | 54.81% | 58.10% | 58.10% |
| FII Holding | 0.29% | 0.23% | 0.16% | 0.18% | 0.17% | 0.17% | 0.16% | 0.15% |
| DII Holding | 0.67% | 0.67% | 0.67% | 0.67% | 0.67% | 0.88% | 0.82% | 0.75% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.06% | 31.18% | 31.41% | 31.52% | 31.42% | 33.90% | 31.48% | 31.67% |
| Other Holding | 9.82% | 9.76% | 9.61% | 9.48% | 9.57% | 10.23% | 9.44% | 9.32% |
| Shareholder Count | 26,727 | 28,472 | 28,189 | 27,743 | 27,155 | 25,717 | 25,699 | 25,716 |
Lyka Labs Share Dividend Screener - Share Yield Analysis
Check Lyka Labs dividend history with payout and yield data.
View Lyka Labs dividend details including ex-dates and amounts for LYKALABS stock.
Lyka Labs Stock Index Membership
See which indices include Lyka Labs stock.
Check LYKALABS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Lyka Labs Market Events Screener - Corporate Actions
Get Lyka Labs corporate actions including splits, bonuses, and buybacks.
Check Lyka Labs stock events that may affect LYKALABS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-10 | 2026-08-10 | Annual General Meeting | NA | 15.66% |
| 2026-06-04 | 2026-06-04 | Merger - Demerger | 100:23 | 0.00% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | -3.64% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -3.07% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -3.01% |
| 2025-08-01 | 2025-08-01 | Annual General Meeting | NA | 4.21% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 1.70% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 5.18% |
| 2025-03-04 | 2025-03-04 | Extraordinary General Meeting | NA | -30.25% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -7.74% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 2.19% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 2.08% |
| 2024-02-20 | 2024-02-20 | Extraordinary General Meeting | NA | 9.92% |
| 2023-02-17 | 2023-02-17 | Extraordinary General Meeting | NA | -16.64% |
Lyka Labs Competitors Screener - Peer Comparison
Screen LYKALABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,025 | 39.02 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 179,377 | 69.00 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 161,381 | 73.80 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 117,800 | 30.47 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 114,771 | 21.60 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 114,692 | 27.03 | 33,593 | -0.44% | 3,998 | 67.04 |
| Lupin | 113,211 | 20.48 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,430 | 53.00 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 93,240 | 25.87 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 83,262 | 92.55 | 6,868 | 22.01% | 890 | 71.63 |
Lyka Labs Company Announcements - News Screener
Screen LYKALABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-02 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-07-02 | Disclosure Under Regulation 7 (2) Read With Regulation 6(2) - Continual Disclosure Of SEBI (Prohibition Of Insider Trading) Regulations 2015 | - |
| 2026-07-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-06-28 | Disclosure Under Regulation 7 (2) Read With Regulation 6(2) - Continual Disclosure Of SEBI (Prohibition Of Insider Trading) Regulations 2015 | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-17 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 - GST | - |
| 2026-06-12 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-06-11 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Clarification On Price Movement Of Share | - |
| 2026-06-11 | Clarification sought from Lyka Labs Ltd | - |
| 2026-06-04 | Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 - NCLT Appellate Tribunal New Delhi Bench | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-26 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-25 | Financial Results For 31St March 2026 | - |
| 2026-05-25 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 25Th May 2026 | - |
| 2026-05-12 | Board Meeting Intimation for Approval Of Audited Results | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-30 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-04-09 | Update On The Scheme Of Amalgamation | - |
| 2026-04-09 | Clarification On Price Movement | - |
| 2026-04-08 | Clarification Sought from Lyka Labs Ltd | - |